TY - JOUR T1 - Complement activity in myasthenia gravis is independent of autoantibody titer and disease severity JF - medRxiv DO - 10.1101/2021.01.15.21249875 SP - 2021.01.15.21249875 AU - Miriam L. Fichtner AU - Michelle D. Hoarty AU - Douangsone D. Vadysirisack AU - Richard J. Nowak AU - Kevin C. O’Connor Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/20/2021.01.15.21249875.abstract N2 - Acetylcholine receptor (AChR) autoantibodies, found in patients with autoimmune myasthenia gravis (MG), can directly contribute to disease pathology through activation of the classical complement pathway. Accordingly, complement inhibitors are used as a therapeutic strategy, but the response can be heterogeneous even though AChR autoantibodies are present. The mechanisms underlying the variable response are not defined. Yet there is a need for further understanding so that responses can be better predicted. There is a broad spectrum of circulating complement activity levels activity among MG patients. It is not clear whether this activity associates with disease burden or the circulating levels of autoantibodies. We measured complement activity and investigated these associations in MG patients as a means to explore candidate biomarkers. Most study subjects had complement activity within the range defined by healthy controls and no association between this activity and disease burden or AChR autoantibody titer was observed. Assays measuring the complement activating properties of AChR autoantibodies are needed to identifying patients expected to respond to complement inhibitor-based treatments.Competing Interest StatementKCO has received research support from Ra Pharma, now a part of UCB Pharma, and is a consultant and equity shareholder of Cabaletta Bio. KCO is the recipient of a sponsored research subaward from the University of Pennsylvania, the primary financial sponsor of which is Cabaletta Bio. KCO has served as consultant/advisor for Alexion Pharmaceuticals and Roche, and has received speaking fees from Alexion. MLF has received research support from Grifols. RJN has received research support from the National Institutes of Health (NIH), Genentech, Alexion Pharmaceuticals, argenx, Annexon Biosciences, Ra Pharmaceuticals, Myasthenia Gravis Foundation of America, Momenta, Immunovant, and Grifols. He has served as consultant/advisor for Alexion Pharmaceuticals, argenx, CSL Behring, Grifols, Ra Pharmaceuticals, Immunovant, Momenta and Viela Bio. MDH was an employee of Ra Pharma when the work was conducted. VDD is an employee of UCB Ra Pharma.Funding StatementThis project was supported by a grants, to KCO and RJN, from Ra Pharmaceuticals, now a part of UCB Pharma, and by a High Impact Clinical Research and Scientific Pilot Project award from the Myasthenia Gravis Foundation of American (MGFA). Additionally, KCO was supported by the National Institute of Allergy and Infectious Diseases of the NIH through grant awards to, under award numbers R01-AI114780 and R21-AI142198; by a Neuromuscular Disease Research program award from the Muscular Dystrophy Association (MDA) to KCO under award number MDA575198. MLF received the SPIN award by Grifols and has further been supported through a DFG Research fellowship (FI 2471/1-1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Human Investigation Committee at the Yale School of MedicineAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data reported in this paper is available upon request. ER -